Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Background The combination of insulin and glucagon-like peptide-1 (GLP-1) receptor agonist therapy improves glycaemic control, induces weight loss, and reduces insulin dose needed in type 2 diabetes. We assessed the efficacy and safety of the GLP-1 receptor agonist liraglutide as an add-on therapy to insulin for overweight adult patients with type 1 diabetes.
Originalsprog | Engelsk |
---|---|
Tidsskrift | The Lancet Diabetes & Endocrinology |
Vol/bind | 4 |
Udgave nummer | 3 |
Sider (fra-til) | 221–232 |
Antal sider | 12 |
ISSN | 2213-8587 |
DOI | |
Status | Udgivet - mar. 2016 |
ID: 150698346